Most people following the peptide story learned the phrase "503A bulks list" in the last two weeks without ever being told what it is a list of. It is worth five minutes, because the answer is the clearest map we have of how this ends.
Three doors, and only three
Under section 503A of the Federal Food, Drug, and Cosmetic Act, a pharmacist compounding a drug from a bulk substance has three ways to qualify that substance. It can comply with an applicable United States Pharmacopeia or National Formulary monograph. If no monograph exists, it can be a component of an FDA-approved drug. If neither is true, it has to appear on a list the agency creates by regulation. That list is the 503A bulks list.
The doors are in order, and they are the only ones. There is no fourth door marked "widely used already."
Why the peptides needed door number three
That structure is the entire reason the Pharmacy Compounding Advisory Committee met on July 23 and 24 and recommended six of seven peptides for the list. A substance only ever reaches a bulks-list vote because the first two doors are shut. Nomination is not a compliment. It is a process of elimination.
Our standing asterisk applies here as much as ever: a committee recommendation is not a rule and not an approval. Formal rulemaking with a public comment window still has to happen, and each substance was evaluated for a specific use, not for everything the internet uses it for. Follow the state of play on our regulatory tracker.
The sentence nobody quotes
The same statute keeps going, and the rest of it is the part that actually protects a patient. A bulk substance must also be manufactured by an establishment registered with the FDA, and it must be accompanied by a valid certificate of analysis. If it is an injection, the preparation itself falls under the sterile compounding standards in USP General Chapter 797, which carry identity, purity, sterility and endotoxin testing with them.
Registered maker. Documented contents. Tested product. Three requirements that have nothing to do with whether a molecule works and everything to do with whether the liquid in the vial is what the label says.
What the other vial has instead
Now hold that list up against a peptide bought from an anonymous overseas seller. No registered establishment. A certificate of analysis that, if it exists at all, was supplied by the seller and cannot be traced. No sterility or endotoxin testing anyone can verify. That is the gap we keep pointing at, and it is a supply problem, not a molecule problem. More on evaluating a source is on our safety page, and the vocabulary is in the glossary.
Peppies is a for-profit venture and a disclosed advocate for a legal, tested pathway, because a market with certificates of analysis in it is the market we want to exist. We do not sell peptides, we are not affiliated with the FDA, nothing here is medical advice, and none of these substances has been evaluated or approved by the FDA for the uses being discussed. Our full interest is stated at /about.
The next step that carries legal weight is rulemaking, not a vote. Get notified when it moves.